304 related articles for article (PubMed ID: 25690034)
1. The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastoma.
Lieber J; Armeanu-Ebinger S; Fuchs J
Int J Mol Sci; 2015 Feb; 16(2):4190-208. PubMed ID: 25690034
[TBL] [Abstract][Full Text] [Related]
2. BH3-mimetic drugs prevent tumour onset in an orthotopic mouse model of hepatoblastoma.
Lieber J; Ellerkamp V; Vogt F; Wenz J; Warmann SW; Fuchs J; Armeanu-Ebinger S
Exp Cell Res; 2014 Mar; 322(1):217-25. PubMed ID: 24355809
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
[TBL] [Abstract][Full Text] [Related]
4. Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737.
Lieber J; Dewerth A; Wenz J; Kirchner B; Eicher C; Warmann SW; Fuchs J; Armeanu-Ebinger S
Oncol Rep; 2013 Feb; 29(2):646-52. PubMed ID: 23229825
[TBL] [Abstract][Full Text] [Related]
5. The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma.
Lieber J; Eicher C; Wenz J; Kirchner B; Warmann SW; Fuchs J; Armeanu-Ebinger S
BMC Cancer; 2011 Aug; 11():362. PubMed ID: 21854558
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells.
Lieber J; Ellerkamp V; Wenz J; Kirchner B; Warmann SW; Fuchs J; Armeanu-Ebinger S
Pediatr Surg Int; 2012 Feb; 28(2):149-59. PubMed ID: 21971946
[TBL] [Abstract][Full Text] [Related]
7. BH3 mimetics reduce adhesion and migration of hepatoblastoma and hepatocellular carcinoma cells.
Vogt F; Lieber J; Dewerth A; Hoh A; Fuchs J; Armeanu-Ebinger S
Exp Cell Res; 2013 Jun; 319(10):1443-50. PubMed ID: 23416067
[TBL] [Abstract][Full Text] [Related]
8. Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies.
Khaw SL; Huang DC; Roberts AW
Pathology; 2011 Oct; 43(6):525-35. PubMed ID: 21881535
[TBL] [Abstract][Full Text] [Related]
9. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.
Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DC; Visvader JE; Lindeman GJ
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2766-71. PubMed ID: 21768359
[TBL] [Abstract][Full Text] [Related]
10. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
[TBL] [Abstract][Full Text] [Related]
11. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
van Delft MF; Wei AH; Mason KD; Vandenberg CJ; Chen L; Czabotar PE; Willis SN; Scott CL; Day CL; Cory S; Adams JM; Roberts AW; Huang DC
Cancer Cell; 2006 Nov; 10(5):389-99. PubMed ID: 17097561
[TBL] [Abstract][Full Text] [Related]
12. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
13. Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells.
Koehler BC; Scherr AL; Lorenz S; Elssner C; Kautz N; Welte S; Jaeger D; Urbanik T; Schulze-Bergkamen H
PLoS One; 2014; 9(9):e106571. PubMed ID: 25192188
[TBL] [Abstract][Full Text] [Related]
14. BH3 mimetics to improve cancer therapy; mechanisms and examples.
Zhang L; Ming L; Yu J
Drug Resist Updat; 2007 Dec; 10(6):207-17. PubMed ID: 17921043
[TBL] [Abstract][Full Text] [Related]
15. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
Lucas KM; Mohana-Kumaran N; Lau D; Zhang XD; Hersey P; Huang DC; Weninger W; Haass NK; Allen JD
Clin Cancer Res; 2012 Feb; 18(3):783-95. PubMed ID: 22173547
[TBL] [Abstract][Full Text] [Related]
16. Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.
Bilardi RA; Anstee NS; Glaser SP; Robati M; Vandenberg CJ; Cory S
Cell Death Dis; 2016 Sep; 7(9):e2351. PubMed ID: 27584789
[TBL] [Abstract][Full Text] [Related]
17. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?
Labi V; Grespi F; Baumgartner F; Villunger A
Cell Death Differ; 2008 Jun; 15(6):977-87. PubMed ID: 18369371
[TBL] [Abstract][Full Text] [Related]
19. Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737.
Stauffer SR
Curr Top Med Chem; 2007; 7(10):961-5. PubMed ID: 17508927
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy.
de Graaff MA; de Rooij MA; van den Akker BE; Gelderblom H; Chibon F; Coindre JM; Marino-Enriquez A; Fletcher JA; Cleton-Jansen AM; Bovée JV
Br J Cancer; 2016 May; 114(11):1219-26. PubMed ID: 27140314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
